- 专利标题： Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
-
申请号： US12782376申请日： 2010-05-18
-
公开(公告)号： US08367063B2公开(公告)日： 2013-02-05
- 发明人: William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- 申请人： William J. Boyle , Eugene Medlock , John K. Sullivan , Robin L. Elliott , Frank Martin , Haichun Huang
- 申请人地址： US CA Thousand Oaks US NJ Princeton
- 专利权人： Amgen, Inc.,Medarex, Inc.
- 当前专利权人： Amgen, Inc.,Medarex, Inc.
- 当前专利权人地址： US CA Thousand Oaks US NJ Princeton
- 代理机构： McDonnell Boehnen Hulbert & Berghoff LLP
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61K39/00 ; C07K16/24 ; C07K16/00
摘要：
Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
公开/授权文献
信息查询
